Nuwellis reports preliminary Q4 revenue of $2.3M, up 42% YoY; FY22 revenue $8.5M, up 8%

Nuwellis, Inc.

2022-FY EPS reported -$83.55 revenue$8,543,000

Preliminary Q4 2022 revenue $2.3M, up 42% YoY; full-year 2022 revenue $8.5M, up 8% YoY.
Pediatrics segment grew 92% YoY; Heart Failure +47%; Critical Care +24%.
Growth driven by commercial team expansion and market penetration beyond heart failure.
CEO cites strong sales momentum and commitment to making Aquadex SmartFlow standard of care.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Nuwellis, Inc. reported the fourth quarter and full year 2022 results: revenue approximately $2.3 million and $8.5 million.

Period: the fourth quarter and full year 2022
Revenue: approximately $2.3 million and $8.5 million
Result: preliminary results

Exact text from the filing

preliminary unaudited results for fourth quarter and full year 2022. Preliminary unaudited revenue for the fourth quarter and full year 2022 is anticipated to be approximately $2.3 million and $8.5 million, respectively, representing an increase of 42% and 8% over the same periods last year. The fourth quarter growth rate reflects benefits from the Company’s

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Nuwellis, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-000924

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.